This summary was created by AI, based on 1 opinions in the last 12 months.
Neogen (NEOG-Q) operates as a products and service provider for food and animal safety. The company has shown healthy sales growth in the last few years, although consensus estimates show a lower growth rate expected over the next few years. The balance sheet is leveraged with significant net debt, and the company is currently reinvesting heavily for growth. Despite expected EPS recovery in 2024 and 2025, experts believe there are better opportunities in the current market.
Neogen is a American stock, trading under the symbol NEOG-Q on the NASDAQ (NEOG). It is usually referred to as NASDAQ:NEOG or NEOG-Q
In the last year, 1 stock analyst published opinions about NEOG-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Neogen.
Neogen was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Neogen.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Neogen published on Stockchase.
On 2024-11-08, Neogen (NEOG-Q) stock closed at a price of $16.23.
NEOG operates as a products and service provider for food and animal safety and is now trading at 29x times' Forward P/E. In the last few years, sales growth has been healthy, with 5-year sales growaround 18%. Having said that, based on consensus estimates, sales are expected to grow by 6% over the next few years. The balance sheet is leveraged with net debt of $662M and net debt/EBITDA of 3.1x. The negative free cash flow comes as the company is currently reinvesting heavily to pursue growth, but this may not show up in the intermeditate term: as noted expected growth over the next few years is only around 6%; EPS dipped in 2023 with inflation and labour pressures, but on an adjusted earnings basis an EPS recovery (but still just back to prior levels) is expected in 2024 and 2025. Still, we think there are better opportunities in the current market.
Unlock Premium - Try 5i Free